Phospho-Insulin Receptor β (Tyr1345) Antibody [L11H12]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
95 kDa

Datasheet & SDS

Biological Description

Specificity
Phospho-Insulin Receptor β (Tyr1345) Antibody [L11H12] detects endogenous levels of total Insulin Receptor β protein only when it is phosphorylated at Tyr1345.

Clone
L11H12

Synonym(s)
Insulin receptor, IR, Insulin receptor subunit beta, CD220, INSR

Background
Phospho‑insulin receptor β (Tyr1345) represents an activated state of the β‑subunit of the insulin receptor, a receptor tyrosine kinase of the insulin/IGF receptor family that controls glucose uptake, metabolism, and growth signaling through ligand‑induced autophosphorylation and recruitment of downstream effectors. The receptor is synthesized as a single precursor that is cleaved into extracellular α and transmembrane β chains, with the β‑subunit carrying the intracellular kinase domain, an activation loop tyrosine cluster that governs catalytic activity, and multiple additional tyrosines including Tyr1345 that serve as regulatory and docking sites once phosphorylated. Autophosphorylation is initiated when insulin binding to the extracellular α‑subunits brings two receptor dimers together, allowing trans‑phosphorylation of the activation loop tyrosines in the kinase domain, which relieves autoinhibition and increases kinase activity toward both receptor tyrosines and cytoplasmic substrates such as IRS proteins and SHC. Subsequent phosphorylation at more distal sites in the C‑terminal tail, including Tyr1345, expands the repertoire of SH2‑domain–containing partners that recognize the receptor, supporting assembly of multi‑protein complexes involved in fine‑tuning signaling strength, receptor endocytosis, and lysosomal targeting. Once activated, phospho‑insulin receptor β drives phosphorylation of IRS1–4, which then recruit PI3K p85 to initiate PI3K–AKT signaling, leading to PIP3 generation, activation of PDK1 and AKT, and downstream events such as GLUT4 translocation to the plasma membrane, suppression of gluconeogenic gene expression through FOXO phosphorylation, and stimulation of mTORC1‑dependent protein synthesis via TSC2 phosphorylation. Parallel phosphorylation of SHC and other adaptors promotes GRB2–SOS recruitment and activation of the RAS–RAF–MEK–ERK pathway, which contributes to gene expression programs linked to growth, survival, and differentiation and cooperates with PI3K–AKT outputs to coordinate metabolic and mitogenic responses to insulin. Phospho‑Tyr1345 is associated with receptor internalization to endosomal and lysosomal compartments, providing a handle to monitor receptor trafficking and down‑regulation, and antibodies directed to this site selectively detect the activated, phosphorylated receptor β‑chain against a background of constant total receptor levels. Dysregulated insulin receptor phosphorylation patterns, including altered kinetics or amplitude of distal β‑subunit phosphotyrosines, accompany states of insulin resistance and type 2 diabetes, where imbalanced activation and termination of PI3K–AKT versus RAS–MAPK signaling contribute to impaired glucose handling and maladaptive growth and survival signaling in metabolic tissues.

Background

Phospho‑insulin receptor β (Tyr1345) represents an activated state of the β‑subunit of the insulin receptor, a receptor tyrosine kinase of the insulin/IGF receptor family that controls glucose uptake, metabolism, and growth signaling through ligand‑induced autophosphorylation and recruitment of downstream effectors. The receptor is synthesized as a single precursor that is cleaved into extracellular α and transmembrane β chains, with the β‑subunit carrying the intracellular kinase domain, an activation loop tyrosine cluster that governs catalytic activity, and multiple additional tyrosines including Tyr1345 that serve as regulatory and docking sites once phosphorylated. Autophosphorylation is initiated when insulin binding to the extracellular α‑subunits brings two receptor dimers together, allowing trans‑phosphorylation of the activation loop tyrosines in the kinase domain, which relieves autoinhibition and increases kinase activity toward both receptor tyrosines and cytoplasmic substrates such as IRS proteins and SHC. Subsequent phosphorylation at more distal sites in the C‑terminal tail, including Tyr1345, expands the repertoire of SH2‑domain–containing partners that recognize the receptor, supporting assembly of multi‑protein complexes involved in fine‑tuning signaling strength, receptor endocytosis, and lysosomal targeting. Once activated, phospho‑insulin receptor β drives phosphorylation of IRS1–4, which then recruit PI3K p85 to initiate PI3K–AKT signaling, leading to PIP3 generation, activation of PDK1 and AKT, and downstream events such as GLUT4 translocation to the plasma membrane, suppression of gluconeogenic gene expression through FOXO phosphorylation, and stimulation of mTORC1‑dependent protein synthesis via TSC2 phosphorylation. Parallel phosphorylation of SHC and other adaptors promotes GRB2–SOS recruitment and activation of the RAS–RAF–MEK–ERK pathway, which contributes to gene expression programs linked to growth, survival, and differentiation and cooperates with PI3K–AKT outputs to coordinate metabolic and mitogenic responses to insulin. Phospho‑Tyr1345 is associated with receptor internalization to endosomal and lysosomal compartments, providing a handle to monitor receptor trafficking and down‑regulation, and antibodies directed to this site selectively detect the activated, phosphorylated receptor β‑chain against a background of constant total receptor levels. Dysregulated insulin receptor phosphorylation patterns, including altered kinetics or amplitude of distal β‑subunit phosphotyrosines, accompany states of insulin resistance and type 2 diabetes, where imbalanced activation and termination of PI3K–AKT versus RAS–MAPK signaling contribute to impaired glucose handling and maladaptive growth and survival signaling in metabolic tissues.

References
https://pubmed.ncbi.nlm.nih.gov/1321605/ https://pubmed.ncbi.nlm.nih.gov/27512793/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%